Edgewise Therapeutics (EWTX) Gets a Buy from Evercore ISI

Tip Ranks
2025.11.18 10:37
portai
I'm PortAI, I can summarize articles.

Evercore ISI analyst Cory Kasimov maintains a Buy rating on Edgewise Therapeutics with a $30 price target. Shares closed at $22.26. Kasimov, a 5-star analyst, has a 16.6% average return. Edgewise has a Strong Buy consensus with a $37 price target, indicating a 66.22% upside. J.P. Morgan also rates it Buy with a $34 target.

Evercore ISI analyst Cory Kasimov maintained a Buy rating on Edgewise Therapeutics yesterday and set a price target of $30.00. The company’s shares closed yesterday at $22.26.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Kasimov is a 5-star analyst with an average return of 16.6% and a 55.60% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Immunome, and Alnylam Pharma.

Edgewise Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $37.00, a 66.22% upside from current levels. In a report released on November 14, J.P. Morgan also maintained a Buy rating on the stock with a $34.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.